Trial Profile
Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections; HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 13 Sep 2013 Primary endpoint 'Viral-load' has not been met according to results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.